JP2015526522A - 1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’h−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶形態 - Google Patents
1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’h−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶形態 Download PDFInfo
- Publication number
- JP2015526522A JP2015526522A JP2015529970A JP2015529970A JP2015526522A JP 2015526522 A JP2015526522 A JP 2015526522A JP 2015529970 A JP2015529970 A JP 2015529970A JP 2015529970 A JP2015529970 A JP 2015529970A JP 2015526522 A JP2015526522 A JP 2015526522A
- Authority
- JP
- Japan
- Prior art keywords
- degrees
- isobenzofuran
- spiro
- azetidine
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims description 57
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 111
- -1 spiro [azetidine-3,1'-isobenzofuran] -1-yl Chemical group 0.000 claims abstract description 75
- 241001465754 Metazoa Species 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 40
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 18
- 206010061217 Infestation Diseases 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 239000007787 solid Substances 0.000 claims description 55
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 38
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 30
- 239000003085 diluting agent Substances 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 21
- 238000002441 X-ray diffraction Methods 0.000 claims description 15
- FLEFKKUZMDEUIP-UHFFFAOYSA-N 1-[6-[5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone Chemical compound C1N(C(=O)CS(=O)(=O)C)CC21C1=CC=C(C=3CC(ON=3)(C=3C=C(Cl)C(F)=C(Cl)C=3)C(F)(F)F)C=C1CO2 FLEFKKUZMDEUIP-UHFFFAOYSA-N 0.000 claims description 14
- 238000001757 thermogravimetry curve Methods 0.000 claims description 14
- 238000001157 Fourier transform infrared spectrum Methods 0.000 claims description 13
- FLEFKKUZMDEUIP-QFIPXVFZSA-N 1-[6-[(5s)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone Chemical compound C1N(C(=O)CS(=O)(=O)C)CC21C1=CC=C(C=3C[C@](ON=3)(C=3C=C(Cl)C(F)=C(Cl)C=3)C(F)(F)F)C=C1CO2 FLEFKKUZMDEUIP-QFIPXVFZSA-N 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000002002 slurry Substances 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 244000144972 livestock Species 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 6
- 229960004816 moxidectin Drugs 0.000 claims description 6
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 claims description 5
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 5
- 229960001614 levamisole Drugs 0.000 claims description 5
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 claims description 5
- 229940099245 milbemycin oxime Drugs 0.000 claims description 5
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960000490 permethrin Drugs 0.000 claims description 5
- 229960002957 praziquantel Drugs 0.000 claims description 5
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 claims description 5
- 229960002245 selamectin Drugs 0.000 claims description 5
- NVEPPWDVLBMNMB-SNAWJCMRSA-N 1-methyl-2-[(e)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4h-pyrimidine Chemical compound CN1CCCN=C1\C=C\C1=C(C)C=CS1 NVEPPWDVLBMNMB-SNAWJCMRSA-N 0.000 claims description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
- FXJRDUKXWHFPND-NSHDSACASA-N 2-[(1s)-1-(2,3-dimethylphenyl)ethyl]-1h-imidazole Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=NC=CN1 FXJRDUKXWHFPND-NSHDSACASA-N 0.000 claims description 4
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 4
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 claims description 4
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims description 4
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 claims description 4
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 4
- 239000005660 Abamectin Substances 0.000 claims description 4
- JFLRKDZMHNBDQS-UCQUSYKYSA-N CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C Chemical compound CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C(=C[C@H]3[C@@H]2CC(=O)O1)C)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C.CC[C@H]1CCC[C@@H]([C@H](C(=O)C2=C[C@H]3[C@@H]4C[C@@H](C[C@H]4C=C[C@H]3C2CC(=O)O1)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)OC)OC)OC)C)O[C@H]6CC[C@@H]([C@H](O6)C)N(C)C JFLRKDZMHNBDQS-UCQUSYKYSA-N 0.000 claims description 4
- 239000005894 Emamectin Substances 0.000 claims description 4
- 239000005899 Fipronil Substances 0.000 claims description 4
- 239000005914 Metaflumizone Substances 0.000 claims description 4
- MIFOMMKAVSCNKQ-HWIUFGAZSA-N Metaflumizone Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)N\N=C(C=1C=C(C=CC=1)C(F)(F)F)\CC1=CC=C(C#N)C=C1 MIFOMMKAVSCNKQ-HWIUFGAZSA-N 0.000 claims description 4
- YRWLZFXJFBZBEY-UHFFFAOYSA-N N-(6-butyl-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCCC1=CC=C2N=C(NC(=O)OC)NC2=C1 YRWLZFXJFBZBEY-UHFFFAOYSA-N 0.000 claims description 4
- 239000005930 Spinosad Substances 0.000 claims description 4
- 229950008167 abamectin Drugs 0.000 claims description 4
- 229960002669 albendazole Drugs 0.000 claims description 4
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 4
- 229960002587 amitraz Drugs 0.000 claims description 4
- QXAITBQSYVNQDR-ZIOPAAQOSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1/N=C/N(C)\C=N\C1=CC=C(C)C=C1C QXAITBQSYVNQDR-ZIOPAAQOSA-N 0.000 claims description 4
- 229960003475 cambendazole Drugs 0.000 claims description 4
- 229950003960 demiditraz Drugs 0.000 claims description 4
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 claims description 4
- 229960003974 diethylcarbamazine Drugs 0.000 claims description 4
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims description 4
- 229960003997 doramectin Drugs 0.000 claims description 4
- CXEGAUYXQAKHKJ-NSBHKLITSA-N emamectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](NC)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CXEGAUYXQAKHKJ-NSBHKLITSA-N 0.000 claims description 4
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims description 4
- 229960002346 eprinomectin Drugs 0.000 claims description 4
- 229960005473 fenbendazole Drugs 0.000 claims description 4
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 claims description 4
- 229940013764 fipronil Drugs 0.000 claims description 4
- FYQGBXGJFWXIPP-UHFFFAOYSA-N hydroprene Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 claims description 4
- 229930000073 hydroprene Natural products 0.000 claims description 4
- 229960002418 ivermectin Drugs 0.000 claims description 4
- 229960003439 mebendazole Drugs 0.000 claims description 4
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 claims description 4
- 229930002897 methoprene Natural products 0.000 claims description 4
- 229950003442 methoprene Drugs 0.000 claims description 4
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 claims description 4
- 229960005121 morantel Drugs 0.000 claims description 4
- 229960001920 niclosamide Drugs 0.000 claims description 4
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000535 oxantel Drugs 0.000 claims description 4
- VRYKTHBAWRESFI-VOTSOKGWSA-N oxantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1 VRYKTHBAWRESFI-VOTSOKGWSA-N 0.000 claims description 4
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004454 oxfendazole Drugs 0.000 claims description 4
- 229950007337 parbendazole Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 claims description 4
- 229940014213 spinosad Drugs 0.000 claims description 4
- 239000004308 thiabendazole Substances 0.000 claims description 4
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 4
- 229960004546 thiabendazole Drugs 0.000 claims description 4
- 235000010296 thiabendazole Nutrition 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 229960000323 triclabendazole Drugs 0.000 claims description 4
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 claims description 3
- 150000008361 aminoacetonitriles Chemical class 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 244000045947 parasite Species 0.000 abstract description 19
- 150000001875 compounds Chemical class 0.000 description 80
- 238000000634 powder X-ray diffraction Methods 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 32
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 26
- 238000009472 formulation Methods 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 239000000273 veterinary drug Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000003595 spectral effect Effects 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 230000009545 invasion Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 244000078703 ectoparasite Species 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241000238876 Acari Species 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 241000244206 Nematoda Species 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000012296 anti-solvent Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000019688 fish Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000001144 powder X-ray diffraction data Methods 0.000 description 5
- 229960005134 pyrantel Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000004544 spot-on Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000255925 Diptera Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000004540 pour-on Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- NYEHUAQIJXERLP-UHFFFAOYSA-N 2-methylsulfonylacetic acid Chemical compound CS(=O)(=O)CC(O)=O NYEHUAQIJXERLP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000242722 Cestoda Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001674048 Phthiraptera Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000507 anthelmentic effect Effects 0.000 description 3
- 229940124339 anthelmintic agent Drugs 0.000 description 3
- 239000000921 anthelmintic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 244000079386 endoparasite Species 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 244000000013 helminth Species 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000011164 primary particle Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OKUKFGKSJZBSBP-UHFFFAOYSA-N tert-butyl 6-bromospiro[1h-2-benzofuran-3,3'-azetidine]-1'-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21C1=CC=C(Br)C=C1CO2 OKUKFGKSJZBSBP-UHFFFAOYSA-N 0.000 description 3
- XGCDBGRZEKYHNV-UHFFFAOYSA-N 1,1-bis(diphenylphosphino)methane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CP(C=1C=CC=CC=1)C1=CC=CC=C1 XGCDBGRZEKYHNV-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000239223 Arachnida Species 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000010268 HPLC based assay Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VQXSOUPNOZTNAI-UHFFFAOYSA-N Pyrethrin I Natural products CC(=CC1CC1C(=O)OC2CC(=O)C(=C2C)CC=C/C=C)C VQXSOUPNOZTNAI-UHFFFAOYSA-N 0.000 description 2
- 239000005927 Pyriproxyfen Substances 0.000 description 2
- 241001481703 Rhipicephalus <genus> Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000242541 Trematoda Species 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical group NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 2
- VJFUPGQZSXIULQ-XIGJTORUSA-N pyrethrin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-XIGJTORUSA-N 0.000 description 2
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 238000010922 spray-dried dispersion Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- GQZFZXWGEAPBCX-UHFFFAOYSA-N tert-butyl 6-acetylspiro[1h-2-benzofuran-3,3'-azetidine]-1'-carboxylate Chemical compound C=1C(C(=O)C)=CC=C2C=1COC21CN(C(=O)OC(C)(C)C)C1 GQZFZXWGEAPBCX-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CFRPSFYHXJZSBI-DHZHZOJOSA-N (E)-nitenpyram Chemical compound [O-][N+](=O)/C=C(\NC)N(CC)CC1=CC=C(Cl)N=C1 CFRPSFYHXJZSBI-DHZHZOJOSA-N 0.000 description 1
- FZRBKIRIBLNOAM-UHFFFAOYSA-N (E,E)-2-propynyl 3,7,11-trimethyl-2,4-dodecadienoate Chemical compound CC(C)CCCC(C)CC=CC(C)=CC(=O)OCC#C FZRBKIRIBLNOAM-UHFFFAOYSA-N 0.000 description 1
- KYDCUUUVEXDDEQ-PSXVWNBSSA-N (r)-[(2s)-1-(acridin-9-ylmethyl)-5-ethenyl-1-azoniabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol Chemical compound C1=CC=C2C(C[N+]34CCC(C(C4)C=C)C[C@H]3[C@H](O)C3=CC=NC4=CC=C(C=C43)OC)=C(C=CC=C3)C3=NC2=C1 KYDCUUUVEXDDEQ-PSXVWNBSSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NSWPERXXSPCRCT-UHFFFAOYSA-N 1-(3,5-dichloro-4-fluorophenyl)-2,2,2-trifluoroethanone Chemical compound FC1=C(Cl)C=C(C(=O)C(F)(F)F)C=C1Cl NSWPERXXSPCRCT-UHFFFAOYSA-N 0.000 description 1
- VRPKAWZUDITUFR-UHFFFAOYSA-N 1-(4-chloro-3,5-difluorophenyl)-2,2,2-trifluoroethanone Chemical compound FC1=CC(C(=O)C(F)(F)F)=CC(F)=C1Cl VRPKAWZUDITUFR-UHFFFAOYSA-N 0.000 description 1
- FLEFKKUZMDEUIP-JOCHJYFZSA-N 1-[6-[(5r)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone Chemical compound C1N(C(=O)CS(=O)(=O)C)CC21C1=CC=C(C=3C[C@@](ON=3)(C=3C=C(Cl)C(F)=C(Cl)C=3)C(F)(F)F)C=C1CO2 FLEFKKUZMDEUIP-JOCHJYFZSA-N 0.000 description 1
- IPODSGLIYFREHI-UHFFFAOYSA-N 1-methylsulfonylethanone Chemical compound CC(=O)S(C)(=O)=O IPODSGLIYFREHI-UHFFFAOYSA-N 0.000 description 1
- KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- QAKXPQSVKFRFHD-UHFFFAOYSA-N 2-methylsulfonylacetaldehyde Chemical compound CS(=O)(=O)CC=O QAKXPQSVKFRFHD-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- XMZZKRNRGGMFPM-UHFFFAOYSA-N 2-sulfonylacetaldehyde Chemical compound O=CC=S(=O)=O XMZZKRNRGGMFPM-UHFFFAOYSA-N 0.000 description 1
- OVMPAVCSOVHNOB-UHFFFAOYSA-N 4-bromo-2-(chloromethyl)-1-iodobenzene Chemical compound ClCC1=CC(Br)=CC=C1I OVMPAVCSOVHNOB-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SWELJVAWQMCJLG-UHFFFAOYSA-N 5-bromo-2-chloro-1,3-difluorobenzene Chemical compound FC1=CC(Br)=CC(F)=C1Cl SWELJVAWQMCJLG-UHFFFAOYSA-N 0.000 description 1
- JYEPRXORSDNHKQ-UHFFFAOYSA-N 6-[5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine] Chemical compound C1=C(Cl)C(F)=C(Cl)C=C1C1(C(F)(F)F)ON=C(C=2C=C3C(C4(CNC4)OC3)=CC=2)C1 JYEPRXORSDNHKQ-UHFFFAOYSA-N 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- 241000238679 Amblyomma Species 0.000 description 1
- 241001147672 Ancylostoma caninum Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000244188 Ascaris suum Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010004194 Bed bug infestation Diseases 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 241001666125 Brachonella contorta Species 0.000 description 1
- 241000244036 Brugia Species 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- 241000243982 Brugia pahangi Species 0.000 description 1
- 241000143302 Brugia timori Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XTSSDNAGQREWQC-SXGWCWSVSA-N CC(C)(C)C1C2=C(C=CC(=C2)C(=O)/C=C(/C3=CC(=C(C(=C3)Cl)F)Cl)\C(F)(F)F)C4(O1)CN(C4)C(=O)O Chemical compound CC(C)(C)C1C2=C(C=CC(=C2)C(=O)/C=C(/C3=CC(=C(C(=C3)Cl)F)Cl)\C(F)(F)F)C4(O1)CN(C4)C(=O)O XTSSDNAGQREWQC-SXGWCWSVSA-N 0.000 description 1
- NJTZSWLQBQJUHK-UHFFFAOYSA-N CCCP(=O)=O Chemical compound CCCP(=O)=O NJTZSWLQBQJUHK-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000253350 Capillaria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241001414835 Cimicidae Species 0.000 description 1
- 241000202814 Cochliomyia hominivorax Species 0.000 description 1
- 241001126267 Cooperia oncophora Species 0.000 description 1
- 241000258922 Ctenocephalides Species 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 244000115658 Dahlia pinnata Species 0.000 description 1
- 241001502026 Dahlia tenuis Species 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 241001218273 Demodex brevis Species 0.000 description 1
- 241001128002 Demodex canis Species 0.000 description 1
- 241000193880 Demodex folliculorum Species 0.000 description 1
- 241000558283 Demodex ursi Species 0.000 description 1
- 241001480819 Dermacentor andersoni Species 0.000 description 1
- 241001481694 Dermanyssus Species 0.000 description 1
- 241000202828 Dermatobia hominis Species 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 241000189163 Dipetalonema Species 0.000 description 1
- 241001137876 Diphyllobothrium Species 0.000 description 1
- 241000243990 Dirofilaria Species 0.000 description 1
- 241000243988 Dirofilaria immitis Species 0.000 description 1
- 241001023203 Dracunculus lutrae Species 0.000 description 1
- 241000092921 Elaeophora schneideri Species 0.000 description 1
- 241000251729 Elasmobranchii Species 0.000 description 1
- 241000530560 Etheostoma sagitta Species 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 241000322646 Felicola Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000006489 Gnathonarium dentatum Species 0.000 description 1
- 241000243992 Haemonchus placei Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000244166 Hymenolepis diminuta Species 0.000 description 1
- 241001547356 Hyostrongylus rubidus Species 0.000 description 1
- 241000543830 Hypoderma bovis Species 0.000 description 1
- 241000257174 Hypoderma lineatum Species 0.000 description 1
- 241000406317 Icelus spatula Species 0.000 description 1
- 241000727698 Ilyoplax punctata Species 0.000 description 1
- 240000005939 Indigofera hendecaphylla Species 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 241001480840 Ixodes hexagonus Species 0.000 description 1
- 241001480843 Ixodes ricinus Species 0.000 description 1
- 241000238703 Ixodes scapularis Species 0.000 description 1
- 241000442132 Lactarius lactarius Species 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000255640 Loa loa Species 0.000 description 1
- 239000005912 Lufenuron Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000142892 Mansonella Species 0.000 description 1
- 241000530522 Mansonella ozzardi Species 0.000 description 1
- 241000142895 Mansonella perstans Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241000819999 Nymphes Species 0.000 description 1
- 241000243981 Onchocerca Species 0.000 description 1
- 241000243987 Onchocerca gibsoni Species 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000238887 Ornithodoros Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000243794 Ostertagia ostertagi Species 0.000 description 1
- 241001446258 Paragonimus kellicotti Species 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000269980 Pleuronectidae Species 0.000 description 1
- 241001649229 Psoroptes Species 0.000 description 1
- 241001649230 Psoroptes ovis Species 0.000 description 1
- 241000157468 Reinhardtius hippoglossoides Species 0.000 description 1
- 240000000685 Ruellia repens Species 0.000 description 1
- 241000766166 Salmincola Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000509416 Sarcoptes Species 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 241000256103 Simuliidae Species 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241001617580 Stephanurus Species 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000244159 Taenia saginata Species 0.000 description 1
- 241000244157 Taenia solium Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001454295 Tetranychidae Species 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 241000607216 Toxascaris Species 0.000 description 1
- 241000244030 Toxocara canis Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 241000571980 Uncinaria stenocephala Species 0.000 description 1
- 241000244002 Wuchereria Species 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229960004500 flubendazole Drugs 0.000 description 1
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 150000002547 isoxazolines Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229930001540 kinoprene Natural products 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 229960000521 lufenuron Drugs 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VMVNZNXAVJHNDJ-UHFFFAOYSA-N methyl 2,2,2-trifluoroacetate Chemical compound COC(=O)C(F)(F)F VMVNZNXAVJHNDJ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950003439 monepantel Drugs 0.000 description 1
- WTERNLDOAPYGJD-SFHVURJKSA-N monepantel Chemical compound C([C@@](C)(NC(=O)C=1C=CC(SC(F)(F)F)=CC=1)C#N)OC1=CC(C#N)=CC=C1C(F)(F)F WTERNLDOAPYGJD-SFHVURJKSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 229940079888 nitenpyram Drugs 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- MHZDONKZSXBOGL-UHFFFAOYSA-N propyl dihydrogen phosphate Chemical compound CCCOP(O)(O)=O MHZDONKZSXBOGL-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000001304 sample melting Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
略語及び定義
略語「DSC」は示差走査熱量測定を指す。
略語「PXRD」又は「pxrd」は粉末X線回折を指し、X線粉末回折(XRPD)とも呼ぶことができる。
略語「FT−IR」はフーリエ変換赤外線分光分析を指す。
結晶形態の性質決定
化合物の結晶状態は、単結晶構造、粉末X線回折パターン(PXRD)、フーリエ変換赤外線(FT−IR)吸収分光分析のパターン及び示差走査熱量測定(DSC)を含む幾つかの結晶学的なパラメータによって記載することができる。
単結晶X線解析
形態Aの単結晶の結晶構造を単結晶X線回折の解析によって測定した。室温にてBruker APEX回折計にてデータの回収を行った。空間群P2(1)に適したSHELXソフトウエアを用いた直接法によって構造を解析した。その後、完全行列最小二乗法によって構造を純化した。非水素原子をすべて見つけ出し、異等方性原子変位パラメータを用いて純化した。窒素及び酸素上に位置する水素原子をフーリエ示差マップから見つけ出し、自由に純化した。残りの水素原子を計算された位置に置き、そのキャリア原子に載せた。最終的な純化には、水素原子すべてに対する等方性変位パラメータが含まれた。絶対構成の解析はフラックパラメータの試験によって行った。この場合、パラメータ=0.002であり絶対構成の決定の範囲内で0.0018の推定標準偏差を伴う。最終的なR指標は3.7%だった。最終的な示差フーリエは、不明の又は見当外れの電子密度がないことを示した。
フーリエ変換赤外線(FT−IR)分光分析の機器及び方法
結晶の形態A及び結晶のラセミ体のFT−IRスペクトルは、本明細書で記載される場合、Pike TechnologiesのMIRacle ATR単反射ATR付属品(ゲルマニウム単反射板)を備えたBruker FT−IR Vertex70分光光度計を用いて取得した。16走査の同時添加と共に4cm−1の分解能でスペクトルを集めた。FT−IRのスペクトルは単反射ATRを用いて記録されたので、試料調製は必要なかった。ATR FT−IRを使用することは、赤外線バンドの相対強度をKBrディスク又はヌジョールマル試料調製を用いた透過FT−IRスペクトルで見られるものとは異なるものをもたらすであろう。ATR FT−IRの性質のために、低い波数でのバンドは高い波数よりもさらに強かった。ブランク試行からスペクトルを差し引き、雰囲気の補正及びベクトルの基準化を行った。
粉末X線回析(PXRD)の機器及び方法
結晶の形態A及び結晶のラセミ体の結晶構造は、本明細書で記載される場合、粉末X線回折(PXRD)を用いて解析した。固定スリットで操作されるLynxEye検出器、並びに40kV及び40mA、K2a波長1.5406オングストロームで操作されるCu源を備えたBruker AXS[英国、Coventry]Endeavor D4を用いてX線回折図を得た。回折図は3〜50度2θの領域で得られた。刻み幅は0.020度2θであり、刻み当たりの取得時間は0.5秒だった。取得の間、試料ホルダーを20rpmで回転させた。解析のために平らな表面を提供するような方法でバックグラウンドゼロのシリカウエハー上に固くない固形物を広げることによって解析用の試料を調製した。Bruker AXSから得たEVAソフトウエアパッケージにてデータを解析した。
示差走査熱量測定(DSC)の機器及び方法
解析は、対応する参照蒸発皿と共に40μLのアルミニウム製の蒸発皿にてMettler ToledoのDSC823eで実施した。1分当たり10℃で25℃から十分に高い温度に試料を加熱し、試料の融解を達成した。StarEソフトウエアパッケージバージョン11にてデータの評価を実施した。
一般的なスキーム/調製
以下のスキーム、調製及び実施例では、以下の触媒/反応物質及び様々な略語には、移動相(MP);N,N−ジメチルホルムアミド(DMF);エタノール(EtOH);メチルtert−ブチルエーテル(MTBE);メタノール(MeOH),テトラヒドロフラン(THF);酢酸エチル(EtOAc);トリフルオロ酢酸(TFA);1,3−ビス(ジフェニルホスフィノ)プロパン(DPPP);アミドカルボニルジイミダゾール(CDI);塩化イソプロピルマグネシウム/塩化リチウム(iPrMgCl−LiCl);t−ブチルオキシカルボニル(BOC);酢酸パラジウム(II)(Pd(OAc)2);水素化ホウ素リチウム(LiBH4);tert−ブチルメチルエーテル(TBME);及び1,2−ジクロロエタン(DCE)が含まれる。
医薬/動物用医薬組成物
本発明の化合物は単独で投与することができるか、又は治療されている特定の種の宿主動物、及び寄生虫が関与する、予想される特定の用途に適する剤形にて投与することができる。一般に、それは、1つ以上の薬剤的に又は動物薬剤的に許容可能な賦形剤、希釈剤、キャリア又はそれらの混合物と関連する製剤として投与されるであろう。用語「賦形剤」、「希釈剤」又は「キャリア」は本発明の化合物又はあらゆる追加の動物用薬剤(たとえば、寄生虫駆除剤)以外のあらゆる成分を記載するのに本明細書で使用される。賦形剤、希釈剤、又はキャリアの選択は、かなりの程度まで、たとえば、投与の特定の方式、賦形剤、希釈剤、キャリア又はそれらの混合物の効果のような因子、溶解性及び安定性、並びに剤形の性質に左右される。賦形剤に加えて、投与される本発明の化合物の量及び化合物で状態又は障害を治療する投与計画は、動物の年齢、体重、性別及び病状、疾患の重症度、投与の経路及び回数を含む種々の因子に左右されるので、大きく変化し得る。
使用方法
本発明はさらに、それを必要とする動物に治療上有効な量の本発明の化合物を投与することによって寄生虫感染又は寄生虫侵入を有する又はそれに感受性である動物にてそのような感染又は侵入を治療する方法を含む。
実施例
調製1:5’−ブロモ−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−カルボン酸tert−ブチル
調製2:5’−アセチル−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−カルボン酸tert−ブチル
調製3:1−(4−クロロ−3,5−ジフルオロフェニル)−2,2,2−トリフルオロエタノン
調製4:5’−(3−(3,5−ジクロロ−4−フルオロフェニル)−4,4,4−トリフルオロブト−2−エノイル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−カルボン酸tert−ブチル
調製5:キラル−tert−ブチル5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−カルボン酸
調製6:キラル−5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]塩酸塩
調製7:キラル−5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]パラ−トルエンスルホネート
調製8:キラル−5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]ベンゼンスルホネート
実施例1:1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノン
実施例2:1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶の形態Aの調製−非晶質S−エナンチオマーの結晶化
元々、結晶の形態Aの種は、100mg〜200mgの間の1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの非晶質S形態を室温でメタノールに溶解することによって調製した。少量のこの溶液をキャップを外した4mLのガラス製バイアルに入れた。数mLのジイソプロピルエーテルを含有するさらに大きい20mLの琥珀色のバイアルに4mLのガラス製バイアルを入れ、次いで20mLバイアルにキャップをした。溶媒の蒸気を5日間、蒸発/拡散させ、この時点で固形物に気付いた。偏光顕微鏡下での固形物の検査は高度に複屈折性の結晶粒子を示した。ホットステージ顕微鏡による分析は130〜170℃の間での融点を示した。さらなる検査によって形態A(たとえば、種結晶)を確認した。
実施例3:(R)−1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶の形態の調製−非晶質R−エナンチオマーの結晶化
結晶形態は、ジエチルエーテルを有する20mLのガラス製バイアルに上記からの非晶質R−エナンチオマー50mgを添加して調製することができる。試料を加熱し、超音波槽にておよそ1時間超音波処理した。非晶質固形物は加熱/超音波処理で溶解すると思われ、次いで固形物が溶液から析出するのが認められた。偏光顕微鏡による固形物の検査は複屈折(結晶化度の指標)を示し得る非常に小さな粒子を示した。懸濁液を20mLのガラス製バイアルから取り出し、PTFE(テフロン(商標))コーティングした磁気撹拌子を有する15mLの密封圧力管に入れた。磁気撹拌しながら、約1時間にわたって加熱し、約3時間にわたって冷却する合計5回の加熱/冷却サイクルで、この管を約20時間にわたって60℃から−10℃に繰り返し加熱及び冷却した。偏光顕微鏡による得られた懸濁液の検査は、加熱/冷却サイクルの前よりもはるかに大きな結晶を示した。少量の得られた固形物を濾過によって懸濁液から単離し、およそ160トールの絶対圧で真空下にて一晩30℃で乾燥させ、PXRDによって分析し、形態Aに類似する回折パターンを得た。固形物をDSCによってまた分析し、146℃(ピーク吸熱)前後の広い融点を示した。
HPLCアッセイ法
およそ(90/10(S/R)のスルホンアミドエナンチオマーのキラルHPLC:ChiralpakIAカラム(250×3.0mm)、定組成50/50メチルtert−ブチルエーテル/0.2%ジエチルアミンを有するエタノール、流速1.0mL/分、260nmでの検出。保持時間:8.5分(Sエナンチオマー)及び16.5分(Rエナンチオマー)。単離された固形物は約99%のS及び1%以下の不活性異性体(R)である。さらなるエナンチオマーの濃縮は、MTBE(たとえば)にて撹拌し、形成するあらゆる固形物を濾過することによって得ることができる。生成物は、以前記載された分取用キラルSFC条件下でラセミ体のエナンチオマーを溶出する最初のものと同一であった。1H−NMR,600MHz(d6−DMSO):7.88(d,2H),7.82(d,1H),7.73(m,2H),5.18(s,2H),4.62(dd,2H),4.42(dd,2H),4.28(m,4H),3.20(s,3H);m/z(CI)582[M+H]。
追加のキラルHPLCアッセイ法
ChiracelAD−3R、150×4.6mm、3ミクロンのカラム、75:25のメタノール:アセトニトリルの定組成溶媒混合物を用いた1.5mL/分の流速。カラム温度40℃。260nmでの検出。保持時間は:S−異性体(4.0分)、R−異性体(7.8分)。実施時間15分。
S−異性体のためのHPLCアッセイ法
ACE Excel、2 C18−AR、150×4.6mmカラム。カラム温度50℃。260nmでの検出。流速は1.5mL/分である。移動相A:水中0.1%トリフルオロ酢酸。移動相B:アセトニトリル中0.1%TFA。勾配での実行:開始時間45%B、4.5分55%B、20分100%B。S−異性体の溶出時間は9.8分である。
Claims (19)
- 1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶形態Aであって、以下の特性:
(a)約17.18、18.83及び20.07にて度2θ(±0.2°)で表される特徴的なピークを有するX線回折パターン;
(b)約17.18、18.83及び20.07にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約4.70、9.39、14.10、15.70、19.12、20.97、21.42、22.03、22.54、23.62、及び28.42でのピークから成る群から選択される度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターン;
(c)約17.18、18.83及び20.07にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約21.42、22.54及び28.42にて度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターン;
(d)約17.18、18.83、20.07、21.42、22.54及び28.42にて度2θ(±0.2°)で表される特徴的なピークを有するX線回折パターン;
(e)実質的に図2で示される、1800〜600cm−1の範囲でのフーリエ変換赤外線スペクトル;
(f)実質的に図3.1で示される、10℃/分の走査速度で約145.53℃にて単一の主要な吸熱を有する示差走査熱量測定のサーモグラム;及び
(g)実質的に図3.2で示される、10℃/分の走査速度で144.01〜146.92℃の範囲内で単一の主要な吸熱を有する示差走査熱量測定のサーモグラム、
の少なくとも1つを示す結晶形態A。 - (i)以下
(a)約17.18、18.83及び20.07にて度2θ(±0.2°)で表される特徴的なピークを有するX線回折パターン;
(b)約17.18、18.83及び20.07にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約21.42、22.54及び28.42にて度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターン;
(c)約17.18、18.83、20.07、21.42及び28.42にて度2θ(±0.2°)で表される特徴的なピークを有するX線回折パターン、
から選択される以下のX線回折パターンの少なくとも1つ;及び
(ii)実質的に図2で示される、1800〜600cm−1の範囲でのフーリエ変換赤外線スペクトル;又は
(iii)実質的に図3.1で示される、10℃/分の走査速度で約145.53℃にて単一の主要な吸熱を有する示差走査熱量計のサーモグラム若しくは実質的に図3.2で示される、10℃/分の走査速度で144.01〜146.92℃の範囲内で単一の主要な吸熱を有する前記示差走査熱量測定のサーモグラム、
を示す請求項1記載の結晶形態。 - 以下の特性:
(a)約17.18、18.83及び20.07にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約4.70、9.39、14.10、15.70、19.12、20.97、21.42、22.03、22.54、23.62、及び28.42にて度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターン;及び
(b)実質的に図2で示される、1800〜600cm−1の範囲でのフーリエ変換赤外線スペクトル、
を示す請求項1記載の結晶形態。 - 以下の特性
(a)約17.18、18.83及び20.07にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約4.70、9.39、14.10、15.70、19.12、20.97、21.42、22.03、22.54、23.62、及び28.42にて度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターン;及び
(b)図3.1で示すような実質的に10℃/分の走査速度で約145.53℃にて単一の主要な吸熱を有する示差走査熱量測定のサーモグラム又は図3.2で示すような実質的に10℃/分の走査速度で144.01〜146.92℃の範囲内で単一の主要な吸熱を有する前記示差走査熱量測定のサーモグラム、
を示す請求項1記載の結晶形態。 - 以下の特性:
(a)実質的に図2で示される、1800〜600cm−1の範囲でのフーリエ変換赤外線スペクトル;及び
(b)実質的に図3.1で示される、10℃/分の走査速度で約145.53℃にて単一の主要な吸熱を有する示差走査熱量測定のサーモグラム又は実質的に図3.2で示される、10℃/分の走査速度で144.01〜146.92℃の範囲内で単一の主要な吸熱を有する前記示差走査熱量測定のサーモグラム、
を示す請求項1記載の結晶形態。 - 約17.18、18.83、20.07にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約21.42、22.54及び28.42にて度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターンを示す請求項1記載の結晶形態。
- 実質的に図2で示される、1800〜600cm−1の範囲でのフーリエ変換赤外線スペクトルを示す請求項1記載の結晶形態。
- 実質的に図3.1で示される、10℃/分の走査速度で約145.53℃にて単一の主要な吸熱を有する示差走査熱量測定のサーモグラム又は実質的に図3.2で示される、10℃/分の走査速度で144.01〜146.92℃の範囲内で単一の主要な吸熱を有する前記示差走査熱量測定のサーモグラムを示す請求項1記載の結晶形態。
- 組成物であって、治療上有効な量の結晶形態A、結晶形態Aから調製される非晶質(S)−1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノン、結晶形態Aから調製される(S)−1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノン、若しくは1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶ラセミ体、又はそれらのいずれかの混合物、及び薬剤的又は動物薬剤的に許容可能な賦形剤、希釈剤、キャリア若しくはそれらの混合物を含む組成物。
- さらに、アバメクチン、セラメクチン、モキシデクチン、イベルメクチン、エマメクチン、ドラメクチン、エプリノメクチン、ピランテル、アミトラズ、アルベンダゾール、カンベンダゾール、フェンベンダゾール、フルベンダゾール、メベンダゾール、フェバンテル、オクタデプシペプチド、オクスフェンダゾール、オキシベンダゾール、パラヘルクアミド、パルベンダゾール、プラジカンテル、チアベンダゾール、テトラアミゾール、トリクラベンダゾール、レバミソール、オキサンテル、ノバルロン、モランテル、ミルベマイシン、ミルベマイシンオキシム、デミジトラズ、ジエチルカルバマジン、フィプロニル、ヒドロプレン、キノプレン、メトプレン、メタフルミゾン、ニクロサミド、ペルメトリン、ピレトリン、ピリプロキシフェン、スピノサド、アミノアセトニトリル誘導体、又はそれらのいずれかの混合物を含む請求項9記載の組成物。
- 動物にて寄生虫感染又は寄生虫侵入を治療する方法であって、それを必要とする動物に治療上有効な量の結晶形態A、結晶形態Aから調製される非晶質(S)−1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノン、結晶形態Aから調製される(S)−1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノン、若しくは1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶ラセミ体、又はそれらのいずれかの混合物を投与することを含む方法。
- さらに、アバメクチン、セラメクチン、モキシデクチン、イベルメクチン、エマメクチン、ドラメクチン、エプリノメクチン、ピランテル、アミトラズ、アルベンダゾール、カンベンダゾール、フェンベンダゾール、フルベンダゾール、メベンダゾール、フェバンテル、オクタデプシペプチド、オクスフェンダゾール、オキシベンダゾール、パラヘルクアミド、パルベンダゾール、プラジカンテル、チアベンダゾール、テトラアミゾール、トリクラベンダゾール、レバミソール、オキサンテル、ノバルロン、モランテル、ミルベマイシン、ミルベマイシンオキシム、デミジトラズ、ジエチルカルバマジン、フィプロニル、ヒドロプレン、キノプレン、メトプレン、メタフルミゾン、ニクロサミド、ペルメトリン、ピレトリン、ピリプロキシフェン、スピノサド、アミノアセトニトリル誘導体、又はそれらのいずれかの混合物から選択される少なくとも1種の追加の動物用薬剤を投与することを含む請求項11記載の方法。
- 前記動物がペット動物又は家畜であり、投与が経口、局所又は注射による請求項11又は12記載の方法。
- 結晶形態Aを調製する方法であって、
(a)非晶質(S)−1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノン固形物を溶媒に充填すること;
(b)前記混合物を約60℃に加熱すること;
(c)前記混合物を約45℃に冷却すること;
(d)形態Aの種を加え、約45℃で保持すること;
(e)前記混合物をゆっくり冷却すること;及び
(f)前記固形物を濾過し、洗浄し、乾燥させること、を含む方法。 - 前記溶媒が、約60%のエタノール、約5%の酢酸エチル、及び約35%のn−ヘプタン、又はそれらの混合物を含む請求項14記載の方法。
- 前記混合物を約15〜20分の時間にわたって約60℃から約45℃に冷却し、形態Aの種を加え、前記混合物を約2時間45℃で保持し、次いで直線的に10℃に冷却し、約4.5時間10℃で保持し、さらに0〜1℃に冷却し、約23時間0〜1℃で保持してスラリーを得る請求項15記載の方法。
- 前記スラリーを真空下で濾過し、n−ヘプタンとエタノールとを含む溶液で前記固形物を洗浄し、さらに真空下で前記固形物を乾燥させて結果として得られる形態Aを得る請求項16記載の方法。
- 以下の特性:
(a)約3.40、18.94及び20.18にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約4.47、4.74、5.23、17.03、19.77、21.17、22.63及び24.18にて度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターン;
(b)約3.40、4.47、4.74、18.94及び20.18にて度2θ(±0.2°)で表される特徴的なピークを有するX線回折パターン;
(c)約3.40、18.94及び20.18にて度2θ(±0.2°)で表される特徴的なピークを有するX線回折パターン;
(d)実質的に図5で示される、1800〜600cm−1の範囲でのフーリエ変換赤外線スペクトル;及び
(e)実質的に図6で示される、10℃/分の走査速度で約241.77℃にて単一の主要な吸熱を有する示差走査熱量測定(DSC)のサーモグラム、
の少なくとも1つを示す1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’H−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶ラセミ体。 - 以下の特性:
(a)約3.40、18.94及び20.18にて度2θ(±0.2°)で表される特徴的なピークを有し、さらに約4.47、4.74、5.23、17.03、19.77、21.17、22.63及び24.18にて度2θ(±0.2°)で表される少なくとも1つの追加の回折ピークを含むX線回折パターン;
(b)実質的に図5で示される、1800〜600cm−1の範囲でのフーリエ変換赤外線スペクトル;又は
(c)実質的に図6で示される、10℃/分の走査速度で約241.77℃にて単一の主要な吸熱を有する示差走査熱量測定(DSC)のサーモグラムの少なくとも2つを示す請求項18記載の結晶形態。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261695410P | 2012-08-31 | 2012-08-31 | |
US61/695,410 | 2012-08-31 | ||
PCT/US2013/056945 WO2014036056A1 (en) | 2012-08-31 | 2013-08-28 | Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015526522A true JP2015526522A (ja) | 2015-09-10 |
JP6109942B2 JP6109942B2 (ja) | 2017-04-05 |
Family
ID=49115603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015529970A Active JP6109942B2 (ja) | 2012-08-31 | 2013-08-28 | 1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’h−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶形態 |
Country Status (29)
Country | Link |
---|---|
US (1) | US9200003B2 (ja) |
EP (1) | EP2890699B1 (ja) |
JP (1) | JP6109942B2 (ja) |
KR (1) | KR101736643B1 (ja) |
CN (1) | CN104812758B (ja) |
AR (1) | AR092409A1 (ja) |
AU (1) | AU2013308887B2 (ja) |
BR (1) | BR112015004135B8 (ja) |
CA (1) | CA2881467C (ja) |
CL (1) | CL2015000332A1 (ja) |
CY (1) | CY1120611T1 (ja) |
DK (1) | DK2890699T3 (ja) |
ES (1) | ES2671271T3 (ja) |
HK (1) | HK1209125A1 (ja) |
HR (1) | HRP20180861T1 (ja) |
HU (1) | HUE037667T2 (ja) |
LT (1) | LT2890699T (ja) |
MX (1) | MX351463B (ja) |
NO (1) | NO2931268T3 (ja) |
NZ (1) | NZ704175A (ja) |
PH (1) | PH12015500441B1 (ja) |
PL (1) | PL2890699T3 (ja) |
PT (1) | PT2890699T (ja) |
RS (1) | RS57284B1 (ja) |
RU (1) | RU2614978C2 (ja) |
SI (1) | SI2890699T1 (ja) |
TR (1) | TR201807735T4 (ja) |
WO (1) | WO2014036056A1 (ja) |
ZA (1) | ZA201500728B (ja) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ704627A (en) | 2012-09-07 | 2016-01-29 | Zoetis Services Llc | Spirocyclic isoxazoline parasiticidal combinations |
AU2013312896A1 (en) * | 2012-09-07 | 2015-02-26 | Zoetis Services Llc | Spirocyclic derivatives as antiparasitic agents |
AR096346A1 (es) * | 2013-05-20 | 2015-12-23 | Zoetis Llc | Composiciones antiparasitarias de espiro-isoxazolina de acción prolongada |
EP3204390B1 (en) | 2014-10-06 | 2019-06-05 | Basf Se | Substituted pyrimidinium compounds for combating animal pests |
US20180368404A1 (en) | 2014-11-06 | 2018-12-27 | Basf Se | 3-pyridyl heterobicyclic compound for controlling invertebrate pests |
US11064696B2 (en) | 2015-04-07 | 2021-07-20 | Basf Agrochemical Products B.V. | Use of an insecticidal carboxamide compound against pests on cultivated plants |
WO2016198613A1 (en) | 2015-06-11 | 2016-12-15 | Basf Se | N-(thio)acylimino compounds |
WO2016198611A1 (en) | 2015-06-11 | 2016-12-15 | Basf Se | N-(thio)acylimino heterocyclic compounds |
WO2017016883A1 (en) | 2015-07-24 | 2017-02-02 | Basf Se | Process for preparation of cyclopentene compounds |
EP3356341B1 (en) | 2015-10-02 | 2020-04-01 | Basf Se | Imino compounds with a 2-chloropyrimidin-5-yl substituent as pest-control agents |
CA3003956A1 (en) | 2015-11-30 | 2017-06-08 | Basf Se | Mixtures of cis-jasmone and bacillus amyloliquefaciens |
US20190077809A1 (en) | 2016-03-09 | 2019-03-14 | Basf Se | Spirocyclic Derivatives |
CN108697089A (zh) | 2016-03-11 | 2018-10-23 | 巴斯夫欧洲公司 | 防除植物害虫的方法 |
BR112018068851B1 (pt) | 2016-04-01 | 2022-11-22 | Basf Se | Composto de fórmula i, composição, métodos de combate ou controle de pragas invertebradas e de proteção de plantas, semente revestida e uso de pelo menos um composto |
WO2018082962A1 (en) * | 2016-11-02 | 2018-05-11 | Basf Se | Process for preparation of tetrahydrothiophene derivatives |
MX2019007120A (es) | 2016-12-16 | 2019-09-16 | Basf Se | Compuestos plaguicidas. |
WO2018162312A1 (en) | 2017-03-10 | 2018-09-13 | Basf Se | Spirocyclic derivatives |
WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
MX2019011626A (es) | 2017-03-28 | 2019-12-05 | Basf Se | Compuestos plaguicidas. |
CN116102580A (zh) | 2017-03-31 | 2023-05-12 | 巴斯夫欧洲公司 | 用于防除动物害虫的嘧啶鎓化合物及其混合物 |
WO2018192793A1 (en) | 2017-04-20 | 2018-10-25 | Basf Se | Substituted rhodanine derivatives |
RU2019136972A (ru) | 2017-04-26 | 2021-05-26 | Басф Се | Замещенные сукцинимидные производные в качестве пестицидов |
IL270403B (en) | 2017-05-10 | 2022-06-01 | Basf Se | Cyclical pesticidal compounds |
WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
WO2018229202A1 (en) | 2017-06-16 | 2018-12-20 | Basf Se | Mesoionic imidazolium compounds and derivatives for combating animal pests |
CN110678469B (zh) | 2017-06-19 | 2023-03-03 | 巴斯夫欧洲公司 | 用于防除动物害虫的取代嘧啶鎓化合物和衍生物 |
WO2018234488A1 (en) | 2017-06-23 | 2018-12-27 | Basf Se | SUBSTITUTED CYCLOPROPYL DERIVATIVES |
WO2019042932A1 (en) | 2017-08-31 | 2019-03-07 | Basf Se | METHOD FOR CONTROLLING RICE PARASITES IN RICE |
EP3453706A1 (en) | 2017-09-08 | 2019-03-13 | Basf Se | Pesticidal imidazole compounds |
EP3694852A1 (en) | 2017-10-13 | 2020-08-19 | Basf Se | Imidazolidine pyrimidinium compounds for combating animal pests |
WO2019099669A1 (en) * | 2017-11-16 | 2019-05-23 | Avista Pharma Solutions, Inc. | Single enantiomer antiparasitic compounds |
BR112020012018A2 (pt) | 2017-12-15 | 2020-11-24 | Tarsus Pharmaceuticals, Inc. | formulações de parasiticida de isoxazolina e métodos para tratar blefarite |
WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
MX2020006566A (es) | 2017-12-21 | 2020-09-25 | Basf Se | Compuestos plaguicidas. |
AU2019211978A1 (en) | 2018-01-09 | 2020-07-09 | Basf Se | Silylethynyl hetaryl compounds as nitrification inhibitors |
WO2019137995A1 (en) | 2018-01-11 | 2019-07-18 | Basf Se | Novel pyridazine compounds for controlling invertebrate pests |
EP3758491A1 (en) | 2018-02-28 | 2021-01-06 | Basf Se | Use of pyrazole propargyl ethers as nitrification inhibitors |
MX2020009022A (es) | 2018-02-28 | 2020-10-12 | Basf Se | Uso de alcoxipirazoles como inhibidores de la nitrificacion. |
US11578012B2 (en) | 2018-02-28 | 2023-02-14 | Basf Se | Use of N-functionalized alkoxy pyrazole compounds as nitrification inhibitors |
WO2019175713A1 (en) | 2018-03-14 | 2019-09-19 | Basf Corporation | New catechol molecules and their use as inhibitors to p450 related metabolic pathways |
WO2019175712A1 (en) | 2018-03-14 | 2019-09-19 | Basf Corporation | New uses for catechol molecules as inhibitors to glutathione s-transferase metabolic pathways |
WO2019185413A1 (en) | 2018-03-27 | 2019-10-03 | Basf Se | Pesticidal substituted cyclopropyl derivatives |
CN112423590B (zh) | 2018-05-15 | 2022-07-08 | 巴斯夫欧洲公司 | 包含benzpyrimoxan和oxazosulfyl的混合物和用途以及它们的施用方法 |
WO2019224092A1 (en) | 2018-05-22 | 2019-11-28 | Basf Se | Pesticidally active c15-derivatives of ginkgolides |
WO2020002472A1 (en) | 2018-06-28 | 2020-01-02 | Basf Se | Use of alkynylthiophenes as nitrification inhibitors |
US20210340073A1 (en) | 2018-07-23 | 2021-11-04 | Basf Se | Use of substituted 2-thiazolines as nitrification inhibitors |
EP3826982B1 (en) | 2018-07-23 | 2023-11-01 | Basf Se | Use of a substituted thiazolidine compound as nitrification inhibitor |
EP3613736A1 (en) | 2018-08-22 | 2020-02-26 | Basf Se | Substituted glutarimide derivatives |
AU2019348280A1 (en) | 2018-09-28 | 2021-04-22 | Basf Se | Method of controlling pests by seed treatment application of a mesoionic compound or mixture thereof |
EP3628156A1 (en) | 2018-09-28 | 2020-04-01 | Basf Se | Method for controlling pests of sugarcane, citrus, rapeseed, and potato plants |
EP3628158A1 (en) | 2018-09-28 | 2020-04-01 | Basf Se | Pesticidal mixture comprising a mesoionic compound and a biopesticide |
EP3628157A1 (en) | 2018-09-28 | 2020-04-01 | Basf Se | Method of controlling insecticide resistant insects and virus transmission to plants |
EP3643705A1 (en) | 2018-10-24 | 2020-04-29 | Basf Se | Pesticidal compounds |
WO2020109039A1 (en) | 2018-11-28 | 2020-06-04 | Basf Se | Pesticidal compounds |
WO2020126591A1 (en) | 2018-12-18 | 2020-06-25 | Basf Se | Substituted pyrimidinium compounds for combating animal pests |
EP3696177A1 (en) | 2019-02-12 | 2020-08-19 | Basf Se | Heterocyclic compounds for the control of invertebrate pests |
EP3769623A1 (en) | 2019-07-22 | 2021-01-27 | Basf Se | Mesoionic imidazolium compounds and derivatives for combating animal pests |
US20220202017A1 (en) | 2019-05-29 | 2022-06-30 | Basf Se | Mesoionic imidazolium compounds and derivatives for combating animal pests |
EP3766879A1 (en) | 2019-07-19 | 2021-01-20 | Basf Se | Pesticidal pyrazole derivatives |
WO2022061914A1 (zh) * | 2020-09-28 | 2022-03-31 | 台州臻挚生物科技有限公司 | 一种3,5-二卤三氟苯乙酮及其衍生物的制备方法 |
CN116829521A (zh) | 2021-02-02 | 2023-09-29 | 巴斯夫欧洲公司 | Dcd和烷氧基吡唑作为硝化抑制剂的协同增效作用 |
AR125955A1 (es) | 2021-05-21 | 2023-08-30 | Basf Se | Uso de un compuesto de alcoxi pirazol n-funcionalizado como inhibidor de nitrificación |
CA3219022A1 (en) | 2021-05-21 | 2022-11-24 | Barbara Nave | Use of ethynylpyridine compounds as nitrification inhibitors |
EP4358725A1 (en) | 2021-06-21 | 2024-05-01 | Basf Se | Metal-organic frameworks with pyrazole-based building blocks |
EP4358847A1 (en) | 2021-06-23 | 2024-05-01 | Kimtron, Inc. | System and method for ultra-close proximity irradiation of rotating biomass |
WO2023203066A1 (en) | 2022-04-21 | 2023-10-26 | Basf Se | Synergistic action as nitrification inhibitors of dcd oligomers with alkoxypyrazole and its oligomers |
WO2024028243A1 (en) | 2022-08-02 | 2024-02-08 | Basf Se | Pyrazolo pesticidal compounds |
CN117263825A (zh) * | 2023-11-23 | 2023-12-22 | 内蒙古百灵科技有限公司 | 一种双甲脒结晶的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011104089A1 (en) * | 2010-02-25 | 2011-09-01 | Syngenta Participations Ag | Process for the preparation of isoxazoline derivatives |
WO2012017359A1 (en) * | 2010-08-05 | 2012-02-09 | Pfizer Inc. | Isoxazoline derivatives as antiparasitic agents |
WO2012086462A1 (ja) * | 2010-12-20 | 2012-06-28 | 日本曹達株式会社 | イソオキサゾリン化合物および有害生物防除剤 |
JP5806743B2 (ja) * | 2011-03-10 | 2015-11-10 | ゾエティス・エルエルシー | 抗寄生虫薬としてのスピロ環式イソオキサゾリン誘導体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102292331A (zh) * | 2009-01-22 | 2011-12-21 | 先正达参股股份有限公司 | 杀虫化合物 |
-
2013
- 2013-08-28 NZ NZ704175A patent/NZ704175A/en unknown
- 2013-08-28 AU AU2013308887A patent/AU2013308887B2/en active Active
- 2013-08-28 RU RU2015107052A patent/RU2614978C2/ru active
- 2013-08-28 DK DK13756985.1T patent/DK2890699T3/en active
- 2013-08-28 PL PL13756985T patent/PL2890699T3/pl unknown
- 2013-08-28 WO PCT/US2013/056945 patent/WO2014036056A1/en active Application Filing
- 2013-08-28 CN CN201380044821.9A patent/CN104812758B/zh active Active
- 2013-08-28 MX MX2015002679A patent/MX351463B/es active IP Right Grant
- 2013-08-28 EP EP13756985.1A patent/EP2890699B1/en active Active
- 2013-08-28 RS RS20180636A patent/RS57284B1/sr unknown
- 2013-08-28 TR TR2018/07735T patent/TR201807735T4/tr unknown
- 2013-08-28 US US14/422,098 patent/US9200003B2/en active Active
- 2013-08-28 BR BR112015004135A patent/BR112015004135B8/pt active IP Right Grant
- 2013-08-28 SI SI201331062T patent/SI2890699T1/en unknown
- 2013-08-28 JP JP2015529970A patent/JP6109942B2/ja active Active
- 2013-08-28 KR KR1020157004953A patent/KR101736643B1/ko active IP Right Grant
- 2013-08-28 LT LTEP13756985.1T patent/LT2890699T/lt unknown
- 2013-08-28 PT PT137569851T patent/PT2890699T/pt unknown
- 2013-08-28 ES ES13756985.1T patent/ES2671271T3/es active Active
- 2013-08-28 HU HUE13756985A patent/HUE037667T2/hu unknown
- 2013-08-28 CA CA2881467A patent/CA2881467C/en active Active
- 2013-08-30 AR ARP130103110A patent/AR092409A1/es unknown
- 2013-12-13 NO NO13863231A patent/NO2931268T3/no unknown
-
2015
- 2015-01-30 ZA ZA2015/00728A patent/ZA201500728B/en unknown
- 2015-02-11 CL CL2015000332A patent/CL2015000332A1/es unknown
- 2015-02-27 PH PH12015500441A patent/PH12015500441B1/en unknown
- 2015-10-12 HK HK15109932.5A patent/HK1209125A1/xx unknown
-
2018
- 2018-05-30 HR HRP20180861TT patent/HRP20180861T1/hr unknown
- 2018-06-13 CY CY181100619T patent/CY1120611T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011104089A1 (en) * | 2010-02-25 | 2011-09-01 | Syngenta Participations Ag | Process for the preparation of isoxazoline derivatives |
WO2012017359A1 (en) * | 2010-08-05 | 2012-02-09 | Pfizer Inc. | Isoxazoline derivatives as antiparasitic agents |
WO2012086462A1 (ja) * | 2010-12-20 | 2012-06-28 | 日本曹達株式会社 | イソオキサゾリン化合物および有害生物防除剤 |
JP5806743B2 (ja) * | 2011-03-10 | 2015-11-10 | ゾエティス・エルエルシー | 抗寄生虫薬としてのスピロ環式イソオキサゾリン誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6109942B2 (ja) | 1−(5’−(5−(3,5−ジクロロ−4−フルオロフェニル)−5−(トリフルオロメチル)−4,5−ジヒドロイソオキサゾール−3−イル)−3’h−スピロ[アゼチジン−3,1’−イソベンゾフラン]−1−イル)−2−(メチルスルホニル)エタノンの結晶形態 | |
US9221835B2 (en) | Spirocyclic derivatives as antiparasitic agents | |
JP5806743B2 (ja) | 抗寄生虫薬としてのスピロ環式イソオキサゾリン誘導体 | |
US9131697B2 (en) | Spirocyclic isoxazolines as antiparasitic agents | |
US20160296499A1 (en) | Spiroindoline Antiparasitic Derivatives | |
AU2013259847B2 (en) | Azetidine derivatives as antiparasitic agents | |
JP2021503465A (ja) | 単一エナンチオマーの抗寄生生物化合物 | |
US9133172B2 (en) | Dihydrofuran azetidine derivatives as antiparasitic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150706 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161121 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170308 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6109942 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |